133 related articles for article (PubMed ID: 30784252)
1. Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC.
Zhang B; Wang H; Wang Q; Xu J; Jiang P; Li W
Minerva Med; 2019 Jun; 110(3):273-275. PubMed ID: 30784252
[No Abstract] [Full Text] [Related]
2. Tumor‑released lncRNA H19 promotes gefitinib resistance via packaging into exosomes in non‑small cell lung cancer.
Lei Y; Guo W; Chen B; Chen L; Gong J; Li W
Oncol Rep; 2018 Dec; 40(6):3438-3446. PubMed ID: 30542738
[TBL] [Abstract][Full Text] [Related]
3. E2F1-induced ferritin heavy chain 1 pseudogene 3 (FTH1P3) accelerates non-small cell lung cancer gefitinib resistance.
Zheng G; Chen W; Li W; Ding Y; Tu P; Chen W
Biochem Biophys Res Commun; 2020 Oct; 530(4):624-631. PubMed ID: 32762943
[TBL] [Abstract][Full Text] [Related]
4. miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Hu FY; Cao XN; Xu QZ; Deng Y; Lai SY; Ma J; Hu JB
J Huazhong Univ Sci Technolog Med Sci; 2016 Dec; 36(6):839-845. PubMed ID: 27924500
[TBL] [Abstract][Full Text] [Related]
5. Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p.
Ma G; Zhu J; Liu F; Yang Y
DNA Cell Biol; 2019 Feb; 38(2):176-183. PubMed ID: 30601026
[TBL] [Abstract][Full Text] [Related]
6. Polyphyllin I modulates MALAT1/STAT3 signaling to induce apoptosis in gefitinib-resistant non-small cell lung cancer.
Yang Q; Chen W; Xu Y; Lv X; Zhang M; Jiang H
Toxicol Appl Pharmacol; 2018 Oct; 356():1-7. PubMed ID: 30076870
[TBL] [Abstract][Full Text] [Related]
7. Effects of STAT3 polymorphisms and pharmacokinetics on the clinical outcomes of gefitinib treatment in patients with EGFR-mutation positive non-small cell lung cancer.
Yokota H; Sato K; Sakamoto S; Okuda Y; Asano M; Takeda M; Nakayama K; Miura M
J Clin Pharm Ther; 2020 Aug; 45(4):652-659. PubMed ID: 32402096
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1.
Zhu J; Tao L; Jin L
Mol Med Rep; 2019 Feb; 19(2):1331-1339. PubMed ID: 30535506
[TBL] [Abstract][Full Text] [Related]
9. Targeting STAT3 signaling overcomes gefitinib resistance in non-small cell lung cancer.
Liu Z; Ma L; Sun Y; Yu W; Wang X
Cell Death Dis; 2021 May; 12(6):561. PubMed ID: 34059647
[TBL] [Abstract][Full Text] [Related]
10. Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Ma P; Zhang M; Nie F; Huang Z; He J; Li W; Han L
Biomed Pharmacother; 2017 Mar; 87():20-26. PubMed ID: 28040594
[TBL] [Abstract][Full Text] [Related]
11. Long non-coding RNA UCA1 induces non-T790M acquired resistance to EGFR-TKIs by activating the AKT/mTOR pathway in EGFR-mutant non-small cell lung cancer.
Cheng N; Cai W; Ren S; Li X; Wang Q; Pan H; Zhao M; Li J; Zhang Y; Zhao C; Chen X; Fei K; Zhou C; Hirsch FR
Oncotarget; 2015 Sep; 6(27):23582-93. PubMed ID: 26160838
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNA CASC9 promotes gefitinib resistance in NSCLC by epigenetic repression of DUSP1.
Chen Z; Chen Q; Cheng Z; Gu J; Feng W; Lei T; Huang J; Pu J; Chen X; Wang Z
Cell Death Dis; 2020 Oct; 11(10):858. PubMed ID: 33056982
[TBL] [Abstract][Full Text] [Related]
13. Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).
Codony-Servat C; Codony-Servat J; Karachaliou N; Molina MA; Chaib I; Ramirez JL; de Los Llanos Gil M; Solca F; Bivona TG; Rosell R
Oncotarget; 2017 Jul; 8(29):47305-47316. PubMed ID: 28521301
[TBL] [Abstract][Full Text] [Related]
14. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Wang H; Fei Z; Jiang H
J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
[TBL] [Abstract][Full Text] [Related]
15. Over-regulation of microRNA-133b inhibits cell proliferation of cisplatin-induced non-small cell lung cancer cells through PI3K/Akt and JAK2/STAT3 signaling pathway by targeting EGFR.
Li B; Ding CM; Li YX; Peng JC; Geng N; Qin WW
Oncol Rep; 2018 Mar; 39(3):1227-1234. PubMed ID: 29344640
[TBL] [Abstract][Full Text] [Related]
16. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
[TBL] [Abstract][Full Text] [Related]
17. EGFR mutation and response of lung cancer to gefitinib.
Toyooka S; Kiura K; Mitsudomi T
N Engl J Med; 2005 May; 352(20):2136; author reply 2136. PubMed ID: 15901872
[No Abstract] [Full Text] [Related]
18. The functional role of long non-coding RNAs and their underlying mechanisms in drug resistance of non-small cell lung cancer.
Zhou H; Feng B; Abudoureyimu M; Lai Y; Lin X; Tian C; Huang G; Chu X; Wang R
Life Sci; 2020 Nov; 261():118362. PubMed ID: 32871184
[TBL] [Abstract][Full Text] [Related]
19. Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.
Pan H; Jiang T; Cheng N; Wang Q; Ren S; Li X; Zhao C; Zhang L; Cai W; Zhou C
Oncotarget; 2016 Aug; 7(31):49948-49960. PubMed ID: 27409677
[TBL] [Abstract][Full Text] [Related]
20. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
